000179295 001__ 179295
000179295 005__ 20240229145539.0
000179295 0247_ $$2doi$$a10.3390/cancers14061484
000179295 0247_ $$2pmid$$apmid:35326635
000179295 0247_ $$2pmc$$apmc:PMC8946708
000179295 037__ $$aDKFZ-2022-00577
000179295 041__ $$aEnglish
000179295 082__ $$a610
000179295 1001_ $$0P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aKharazmi, Elhamalsadat$$b0$$eFirst author
000179295 245__ $$aRisk of Gynecological Cancers in Cholecystectomized Women: A Large Nationwide Cohort Study.
000179295 260__ $$aBasel$$bMDPI$$c2022
000179295 3367_ $$2DRIVER$$aarticle
000179295 3367_ $$2DataCite$$aOutput Types/Journal article
000179295 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685707965_5388
000179295 3367_ $$2BibTeX$$aARTICLE
000179295 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179295 3367_ $$00$$2EndNote$$aJournal Article
000179295 500__ $$a#EA:C120#LA:C120#
000179295 520__ $$aBackground: Gallstones affect women more frequently than men, and symptomatic gallstones are increasingly treated with surgical removal of the gallbladder (cholecystectomy). Breast, endometrial, and ovarian cancer share several risk factors with gallstones, including overweight, obesity, and exposure to female sex hormones. We intended to assess the association between cholecystectomy and female cancer risk, which has not been comprehensively investigated. Methods: We investigated the risk of female cancers after cholecystectomy leveraging the Swedish Cancer, Population, Patient, and Death registries. Standardized incidence ratios (SIRs) adjusted for age, calendar period, socioeconomic status, and residential area were used to compare cancer risk in cholecystectomized and non-cholecystectomized women. Results: During a median follow-up of 11 years, 325,106 cholecystectomized women developed 10,431 primary breast, 2888 endometrial, 1577 ovarian, and 705 cervical cancers. The risk of ovarian cancer was increased by 35% (95% confidence interval (CI) 2% to 77%) in the first 6 months after cholecystectomy. The exclusion of cancers diagnosed in the first 6 months still resulted in an increased risk of endometrial (19%, 95%CI 14% to 23%) and breast (5%, 95%CI 3% to 7%) cancer, especially in women cholecystectomized after age 50 years. By contrast, cholecystectomized women showed decreased risks of cervical (-13%, 95%CI -20% to -7%) and ovarian (-6%, 95%CI -10% to -1%) cancer. Conclusions: The risk of ovarian cancer increased by 35% in a just short period of time (6 months) following the surgery. Therefore, it is worth ruling out ovarian cancer before cholecystectomy. Women undergoing cholecystectomy showed an increased risk of breast and endometrial cancer up to 30 years after surgery. Further evaluation of the association between gallstones or gallbladder removal on female cancer risk would allow for the assessment of the need to intensify cancer screening in cholecystectomized women.
000179295 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179295 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179295 650_7 $$2Other$$abreast cancer
000179295 650_7 $$2Other$$acervical cancer
000179295 650_7 $$2Other$$acholecystectomy
000179295 650_7 $$2Other$$aendometrial cancer
000179295 650_7 $$2Other$$agallbladder surgery
000179295 650_7 $$2Other$$alarge nationwide cohort
000179295 650_7 $$2Other$$aovarian cancer
000179295 7001_ $$aSundquist, Kristina$$b1
000179295 7001_ $$aSundquist, Jan$$b2
000179295 7001_ $$0P:(DE-He78)b510b884502b619724039bf33fdae68a$$aFallah, Mahdi$$b3$$eLast author
000179295 7001_ $$00000-0002-6568-5333$$aBermejo, Justo Lorenzo$$b4
000179295 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14061484$$gVol. 14, no. 6, p. 1484 -$$n6$$p1484$$tCancers$$v14$$x2072-6694$$y2022
000179295 909CO $$ooai:inrepo02.dkfz.de:179295$$pVDB
000179295 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179295 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b510b884502b619724039bf33fdae68a$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000179295 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179295 9141_ $$y2022
000179295 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000179295 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000179295 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000179295 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000179295 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000179295 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000179295 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000179295 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000179295 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000179295 980__ $$ajournal
000179295 980__ $$aVDB
000179295 980__ $$aI:(DE-He78)C120-20160331
000179295 980__ $$aUNRESTRICTED